Clinicopathological and prognostic significance of GLUT1 in breast cancer: A meta-analysis.
Medicine (Baltimore)
; 97(48): e12961, 2018 Nov.
Article
em En
| MEDLINE
| ID: mdl-30508885
ABSTRACT
BACKGROUND:
Previous studies examining the prognostic value of glucose transporter 1 in breast cancer have yielded inconsistent results. We, therefore, performed a meta-analysis to clarify this issue.METHODS:
The research was reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Relevant studies were retrieved from PubMed, Web of Science, EMBASE, and Cochrane library.RESULTS:
A total of 7 reports with 1861 patients were finally chosen. GLUT1 overexpression was found to be associated with high histological grade (ORâ=â3.74, 95% CIâ=â2.45-5.69, Pâ<â.001), negative PR status (ORâ=â0.33, 95% CIâ=â0.22-0.49, Pâ<â.001), and negative estrogen receptor (ER) status (ORâ=â0.27, 95% CIâ=â0.17-0.42, Pâ<â.001). However, no significant correlation was seen between GLUT1 levels and presence of lymph node metastasis, tumor size or the status of human epidermal growth factor receptor 2 (HER2). Overexpression of GLUT1 also correlated with a poor overall survival (hazard ratio [HR]â=â1.65, 95% confidence interval [CI]â=â1.17-2.31, Pâ=â.004) and disease-free survival (HRâ=â2.35, 95% CIâ=â1.4-3.94, Pâ<â.001). No evidence of significant publication bias was found.CONCLUSION:
This meta-analysis indicates that GLUT1 expression is associated with poor prognostic and a series of clinicopathological features in breast cancer. GLUT1 might be a potential biomarker and therapeutic target in breast cancer.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Transportador de Glucose Tipo 1
Tipo de estudo:
Guideline
/
Prognostic_studies
/
Systematic_reviews
Limite:
Female
/
Humans
Idioma:
En
Revista:
Medicine (Baltimore)
Ano de publicação:
2018
Tipo de documento:
Article